Medical iSight Establishes Neuroradiology Collaboration with NYU Langone Health

Medical iSight Corp (‘MiS’), developer of a next-generation 3D digital surgery platform, is pleased to announce a development partnership with NYU Langone Health’s Division of Neuroradiology.

The collaboration will further test MiS’ visualization, navigation, and predictive clinical insight algorithms on the image-guided removal of blood clots (thrombectomy) after a stroke, or on blood vessel repair after an aneurysm. The tool is designed to improve procedures that require that a catheter be placed in the groin or wrist, which then must be guided through blood vessels (e.g. carotid arteries, Aorta) to the damaged area.

NYU Langone has an equity interest in MiS as part of the collaboration.

Medical iSight, based in New York and London, is looking forward to working with NYU Langone’s interventional radiologists and neurosurgeons to improve preoperative planning and intraoperative navigation to speed clot removal and lessen ischemic tissue damage for stroke victims. Strokes kill 5.5 million people every year and is the second leading cause of death and the third leading cause of disability worldwide.

Platform Expansion

Medical iSight’s CEO, Justin Hall-Tipping, commented: “We are delighted to be working with NYU Langone Health and their world-class doctors to advance our groundbreaking interventional software and deliver on our vision to unite surgical digital information within a single cognitive platform, to make it universally accessible, thereby resulting in better patient outcomes.”

Hot this week

Recor Medical Supports European Society of Cardiology’s Hypertension Guidelines

Record Medical notes the new guidelines, "2024 ESC Guidelines for the management of elevated blood pressure and hypertension," have been published online and recommend the consideration of renal denervation (RDN) as a safe and effective treatment option for patients who have uncontrolled resistant hypertension or those that have uncontrolled hypertension with a higher risk of cardiovascular disease, who express a preference to undergo RDN.

ConTIPI Medical Selects EVERSANA to Support U.S. Commercialization of Non-Surgical Medical Device ProVate for Women with Pelvic Organ Prolapse

EVERSANA is a leading provider of global commercial services to the life sciences industry, to support commercialization for the ProVate device in the United States to help women experiencing pelvic organ prolapse.

Boston Scientific Obtains CE Mark for ACURATE Prime Aortic Valve System

The ACURATE Prime aortic valve system is designed with several features to build upon the clinical performance of the ACURATE neo2™ platform including an additional valve size, which expands the treatment range to patients with a larger anatomy.

Noctrix Health Announces New CMS Reimbursement Codes and Payment for Nidra Tonic Motor Activation Therapy for Restless Legs Syndrome

Nidra TOMAC Tonic Motor Activation Therapy, which was authorized for marketing in the United States last year following its designation as a "Breakthrough Device" by the US Food & Drug Administration (FDA), remains the only clinically validated, non-pharmaceutical treatment available for patients with RLS.

Haemonetics Announces Full Market Release for VASCADE MVP® XL Vascular Closure System

Haemonetics notes the VASCADE MVP XL system is now available to U.S. hospitals as the newest addition to Haemonetics' VASCADE® portfolio of vascular closure systems featuring an innovative collapsible disc technology and a proprietary resorbable collagen patch designed to promote rapid hemostasis.